1-8 of 8
Jennifer Wheler
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic

Free
Chad Tang, Kenneth Hess, Denis Leonardo F. Jardim, Debora De Melo Gagliato, Apostolia M. Tsimberidou, Gerald Falchook, Siqing Fu, Filip Janku, Aung Naing, Sarina Piha-Paul, Vivek Subbiah, Jennifer Wheler, Ralph G. Zinner, Razelle Kurzrock, Lee M. Ellis, Funda Meric-Berstam, David S. Hong
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (23): 5956–5963.
https://doi.org/10.1158/1078-0432.CCR-14-1582
Published: 30 November 2014
View articletitled, Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic
Open the PDF for Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic in another window
Includes: Supplementary data
Journal Articles

Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial

Free
Ana M. Gonzalez-Angulo, Funda Meric-Bernstam, Sant Chawla, Gerald Falchook, David Hong, Argun Akcakanat, Huiqin Chen, Aung Naing, Siqing Fu, Jennifer Wheler, Stacy Moulder, Thorunn Helgason, Shaoyi Li, Ileana Elias, Neil Desai, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19): 5474–5484.
https://doi.org/10.1158/1078-0432.CCR-12-3110
Published: 01 October 2013
View articletitled, Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial
Open the PDF for Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial in another window
Includes: Supplementary data
Journal Articles

Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity

Free
John Moroney, Siqing Fu, Stacy Moulder, Gerald Falchook, Thorunn Helgason, Charles Levenback, David Hong, Aung Naing, Jennifer Wheler, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (20): 5796–5805.
https://doi.org/10.1158/1078-0432.CCR-12-1158
Published: 14 October 2012
View articletitled, Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity
Open the PDF for Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity in another window
Journal Articles

A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas

Free
David S. Hong, Razelle Kurzrock, Jeffrey G. Supko, Xiaoying He, Aung Naing, Jennifer Wheler, Donald Lawrence, Joseph Paul Eder, Colin J. Meyer, Deborah A. Ferguson, James Mier, Marina Konopleva, Sergej Konoplev, Michael Andreeff, Donald Kufe, Hillard Lazarus, Geoffrey I. Shapiro, Bruce J. Dezube
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (12): 3396–3406.
https://doi.org/10.1158/1078-0432.CCR-11-2703
Published: 14 June 2012
View articletitled, A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
Open the PDF for A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas in another window
Includes: Supplementary data
Journal Articles

Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience

Free
Jennifer Wheler, Apostolia M. Tsimberidou, David Hong, Aung Naing, Gerald Falchook, Sarina Piha-Paul, Siqing Fu, Stacy Moulder, Bettzy Stephen, Sijin Wen, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10): 2922–2929.
https://doi.org/10.1158/1078-0432.CCR-11-2217
Published: 14 May 2012
View articletitled, Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience
Open the PDF for Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience in another window
Includes: Supplementary data
Journal Articles

A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer

Free
David S. Hong, Razelle Kurzrock, Yun Oh, Jennifer Wheler, Aung Naing, Les Brail, Sophie Callies, Valérie André, Sunil K. Kadam, Aejaz Nasir, Timothy R. Holzer, Funda Meric-Bernstam, Mayer Fishman, George Simon
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (20): 6582–6591.
https://doi.org/10.1158/1078-0432.CCR-11-0430
Published: 14 October 2011
View articletitled, A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer
Open the PDF for A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Clinical Trial Outcomes in 93 Patients with Brain Metastases: The MD Anderson Cancer Center Experience

Free
Apostolia Maria Tsimberidou, Katherine Letourneau, Sijin Wen, Jennifer Wheler, David Hong, Aung Naing, Nancy G. Iskander, Cynthia Uehara, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (12): 4110–4118.
https://doi.org/10.1158/1078-0432.CCR-10-3095
Published: 15 June 2011
View articletitled, Phase I Clinical Trial Outcomes in 93 Patients with Brain Metastases: The MD Anderson Cancer Center Experience
Open the PDF for Phase I Clinical Trial Outcomes in 93 Patients with Brain Metastases: The MD Anderson Cancer Center Experience in another window
Includes: Supplementary data
Journal Articles

Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

Free
Rajul K. Jain, J. Jack Lee, David Hong, Maurie Markman, Jing Gong, Aung Naing, Jennifer Wheler, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (4): 1289–1297.
https://doi.org/10.1158/1078-0432.CCR-09-2684
Published: 15 February 2010
View articletitled, Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse
Open the PDF for Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse in another window
Includes: Supplementary data